GlassScriptPhysician profile
Nancy Caroline Roe
NPI 1124680673
$6,327.29
in general payments reported to CMS, 2019-2025
27 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $882 · 2023: $652 · 2024: $1,524 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,910 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,909.87 |
| Education | $123.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.79 | 2021-2025 | |
| Janssen Biotech, INC. | $659.87 | 2021-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $531.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $412.65 | 2021-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $305.12 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.33 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $194.01 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $164.21 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $150.82 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $148.67 | 2021-2025 | Suflave, Sutab |
| Evoke Pharma, INC. | $142.75 | 2021-2025 | Gimoti |
| Ironwood Pharmaceuticals, INC | $123.46 | 2023-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $109.91 | 2024-2025 | Dupixent |
| Genzyme Corporation | $107.80 | 2024-2025 | |
| Celltrion USA INC. | $75.07 | 2024-2025 | Vegzelma, Zymfentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $60.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $57.61 | 2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $40.94 | 2021 | |
| Redhill Biopharma INC. | $35.94 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $31.84 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $30.30 | 2023 | |
| Enterra Medical, INC. | $27.94 | 2025 | |
| Daiichi Sankyo INC. | $25.25 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.93 | 2023 | Cyltezo |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Merck Sharp & Dohme LLC | $17.58 | 2022 | |
| Dexcom, INC. | $17.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.